Stock grants to Cartesian (NASDAQ: RNAC) COO Emily English disclosed

Rhea-AI Filing Summary

Cartesian Therapeutics Chief Operations Officer Emily English reported new equity awards in the company’s stock. On January 2, 2026, she received 24,000 shares of common stock at a price of $0, bringing her directly owned common stock holdings to 94,226 shares.

On the same date, she was granted an employee stock option for 71,000 shares of common stock at an exercise price of $6.76 per share, expiring on January 1, 2036. The restricted stock units vest 25% on January 2, 2027, with the rest vesting in three equal annual installments through January 2, 2030, while the option vests 25% on January 2, 2027, and the remaining 75% in 36 equal monthly installments thereafter.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider English Emily

Role Chief Operations Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	71,000	$0.00	--
Grant/Award	Common Stock	24,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 71,000 shares (Direct); Common Stock — 94,226 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

English Emily

(Last) (First) (Middle)

C/O CARTESIAN THERAPEUTICS, INC.

7495 NEW HORIZON WAY

(Street)

FREDERICK MD 21703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cartesian Therapeutics, Inc. [ RNAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		24,000	A(1)	$0	94,226	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$6.76	01/02/2026		A		71,000		(2)	01/01/2036	Common Stock	71,000	$0	71,000	D

Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.

2. This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

Remarks:

	/s/ Matthew Bartholomae, Attorney-in-Fact for Emily English	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RNAC’s COO Emily English report on this Form 4?

Emily English, Chief Operations Officer of Cartesian Therapeutics, Inc. (RNAC), reported receiving 24,000 shares of common stock and an option to buy 71,000 shares of common stock on January 2, 2026.

How many Cartesian Therapeutics shares does Emily English own after this transaction?

After the reported transaction, Emily English beneficially owned 94,226 shares of Cartesian Therapeutics common stock in direct ownership.

What are the terms of the 71,000-share stock option granted to RNAC’s COO?

The employee stock option covers 71,000 shares of Cartesian Therapeutics common stock with an exercise price of $6.76 per share and an expiration date of January 1, 2036.

How do the restricted stock units granted to RNAC’s COO vest?

Each restricted stock unit represents one share of common stock. 25% of the award vests on January 2, 2027, and the remaining shares vest in three equal annual installments so that all are fully vested by January 2, 2030.

What is the vesting schedule for the stock options granted to Emily English at Cartesian Therapeutics?

The option vests as to 25% of the 71,000 shares on January 2, 2027. The remaining 75% vests in 36 equal monthly installments after that date.

Are the reported RNAC equity awards to the COO held directly or indirectly?

Both the 24,000 shares of common stock and the 71,000-share employee stock option are reported as held in direct ownership by Emily English.